Sunday, 16 June 2019

I-Mab partners with CSPC for long-acting GLP-1 Fc Program

17 December 2018 | News

CSPC will pay a down payment 15 million RMB in order to be granted an exclusive license to conduct the clinical development and commercialization of TG103 in China.

I-Mab Biopharma (I-Mab), a China-based clinical-stage biopharmaceutical company focused on the development of innovative biologics in immuno-oncology and autoimmune diseases and CSPC Pharmaceutical Group Co., Ltd. (CSPC),a leading pharmaceutical group in China, jointly announced a strategic partnership between the two companies.

Under the partnership, I-Mab's will grant an exclusive license to CSPC to develop I-Mab's long-acting GLP-1 Fc program (TG103) in China.

Under the terms of the agreement, CSPC will pay a down payment 15 million RMB in order to be granted an exclusive license to conduct the clinical development and commercialization of TG103 in China. In addition, CSPC will pay I- Mab 135 million RMB based on further milestone payments as part of the royalties, contribute to the development costs and pay a percentage of sales. CSPC will have the exclusive rights to fund and execute.

TG103 is an innovative, long-acting recombinant glucagon-like peptide-1 (GLP-1) for which I-Mab has achieved IND approval as a Fc-fusion with extended half-life. TG103 enables once-weekly or bi-weekly subcutaneous administration, which can significantly improve convenience and as a result to improve patient treatment compliance. In preclinical studies, and the on-going Phase I trial conducted in Germany, TG103 demonstrated a good safety profile, providing opportunity for drug combination.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Is Asia becoming the centre of healthcare transformation?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls